JP2021531347A - Fcrn抗体組成物 - Google Patents
Fcrn抗体組成物 Download PDFInfo
- Publication number
- JP2021531347A JP2021531347A JP2021526405A JP2021526405A JP2021531347A JP 2021531347 A JP2021531347 A JP 2021531347A JP 2021526405 A JP2021526405 A JP 2021526405A JP 2021526405 A JP2021526405 A JP 2021526405A JP 2021531347 A JP2021531347 A JP 2021531347A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- seq
- heavy chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title description 12
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 21
- 235000004252 protein component Nutrition 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 35
- 230000001605 fetal effect Effects 0.000 description 28
- 230000001717 pathogenic effect Effects 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000028993 immune response Effects 0.000 description 22
- 241000894007 species Species 0.000 description 20
- 230000009385 viral infection Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 208000023275 Autoimmune disease Diseases 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 10
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 206010025135 lupus erythematosus Diseases 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 201000001981 dermatomyositis Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 206010047115 Vasculitis Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 230000008774 maternal effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108010068617 neonatal Fc receptor Proteins 0.000 description 6
- 208000005987 polymyositis Diseases 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 5
- 208000001640 Fibromyalgia Diseases 0.000 description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 208000023328 Basedow disease Diseases 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 208000015023 Graves' disease Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000036473 myasthenia Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 208000026872 Addison Disease Diseases 0.000 description 3
- 208000008190 Agammaglobulinemia Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
- 201000002829 CREST Syndrome Diseases 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 208000027530 Meniere disease Diseases 0.000 description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 3
- 208000021908 Myocardial disease Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 206010065159 Polychondritis Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 208000033464 Reiter syndrome Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 206010003230 arteritis Diseases 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 208000000594 bullous pemphigoid Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000003278 cryoglobulinemia Diseases 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 3
- 229950010333 exalamide Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 208000002741 leukoplakia Diseases 0.000 description 3
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 208000002574 reactive arthritis Diseases 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 206010039722 scoliosis Diseases 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000031976 Channelopathies Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000014447 Complement C1q Human genes 0.000 description 2
- 108010078043 Complement C1q Proteins 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000017118 fetal and neonatal alloimmune thrombocytopenia Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000001296 transplacental effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
- 208000017309 Autoimmune hemolytic anemia, warm type Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010060774 Chondrosis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000018712 Hemolytic disease due to fetomaternal alloimmunization Diseases 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000004692 Pneumovirus Infections Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001455645 Rabbitpox virus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 239000004268 Sodium erythorbin Substances 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000015557 immune complex mediated vasculitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000021356 neonatal antiphospholipid syndrome Diseases 0.000 description 1
- 208000021287 neonatal autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 208000035603 warm type autoimmune hemolytic anemia Diseases 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
- H01J49/165—Electrospray ionisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
Abstract
Description
本発明は、ヒト新生児Fc受容体(FcRn)に標的化された抗体を含む新規の組成物を特色とする。これらの組成物は、例えば、対象における自己抗体のクリアランスを促進するのに、対象における抗原提示を抑制するのに、免疫応答を遮断する(例えば、対象における免疫応答の免疫複合体に基づく活性化を遮断する)のに、または対象における免疫学的疾患(例えば、自己免疫疾患)を治療するのに有用である。本明細書において、前述の単離された抗体および1つまたは複数のサイズバリアントを含有する組成物であって、最終組成物は、約140,000〜143,000(例えば、141,750〜141,800)Daの分子量を有する完全に組み立てられた軽鎖−重鎖−重鎖−軽鎖(LC−HC−HC−LC)を含む、総タンパク質含有量の少なくとも80%、およびより低分子量(例えば、118,000〜120,000Da)の選択サイズバリアントを含む、総タンパク質含有量の最高5%まで(4%、3%、2%、1%、0.8%)を含有する、組成物が開示される。
本明細書において記載されるように製剤化され得る抗体には、軽鎖配列
抗FcRn抗体は、宿主細胞から産生され得る。宿主細胞とは、本明細書において記載されるポリペプチドおよび構築物をそれらの対応する核酸から発現させるために必要とされる必須の細胞構成要素、例えば細胞小器官を含むビヒクルを指す。核酸は、当技術分野において公知の従来技法(例えば、形質転換、トランスフェクション、エレクトロポレーション、リン酸カルシウム沈殿、直接マイクロインジェクション、感染等)によって宿主細胞に導入され得る核酸ベクターに含まれ得る。核酸ベクターの選定は、一部には、使用される対象となる宿主細胞に依存する。一般的に、好ましい宿主細胞は、原核生物(例えば、細菌)または真核生物(例えば、哺乳類)起源のものである。
抗FcRn抗体のアミノ酸配列をコードする核酸配列は、当技術分野において公知の多様な方法によって調製され得る。これらの方法には、オリゴヌクレオチド媒介性(または部位指向性)変異導入およびPCR変異導入が含まれるが、それらに限定されるわけではない。抗FcRn抗体をコードする核酸分子は、標準的技法、例えば遺伝子合成を使用して獲得され得る。あるいは、野生型抗FcRn抗体をコードする核酸分子は、当技術分野における標準的技法、例えばQuikChange(商標)変異導入を使用して、特異的アミノ酸置換を含有するように変異し得る。核酸分子は、ヌクレオチド合成機またはPCR技法を使用して合成され得る。
抗FcRn抗体を産生するために使用される宿主細胞を、当技術分野において公知でかつ選択された宿主細胞の培養に適した培地中で成長させ得る。哺乳類宿主細胞のための適切な培地の例には、最小必須培地(MEM)、ダルベッコ改変イーグル培地(DMEM)、Expi293(商標)発現培地、ウシ胎仔血清(FBS)を補給されたDMEM、およびRPMI−1640が含まれる。細菌宿主細胞のための適切な培地の例には、選択剤、例えばアンピシリン等の必要な補給剤を加えたルリアブロス(LB)が含まれる。宿主細胞を、約20℃〜約39℃、例えば25℃〜約37℃、好ましくは37℃等の適切な温度、および5〜10%(好ましくは8%)等のCO2レベルで培養する。培地のpHは、主に宿主生物に応じて、一般的に約6.8〜7.4、例えば7.0である。発現ベクターにおいて誘導性プロモーターが使用される場合、タンパク質発現は、プロモーターの活性化に適した条件下で誘導される。
本明細書において記載される抗FcRn抗体を含有する薬学的組成物によるヒトFcRnの遮断は、IgG自己抗体によって推進される疾患において治療上有益であり得る。全体的なIgG異化、および複数の種の自己抗体、小型循環代謝産物、またはリポタンパク質の除去を誘導するFcRn遮断の能力は、自己抗体により推進される自己免疫疾患病理を有する患者まで、自己抗体除去ストラテジーの実用性および利用可能性を拡大する方法を与える。いかなる理論によっても拘束されることなく、抗FcRn抗体の作用の支配的メカニズムは、循環における病原性自己抗体の異化を増加させ、ならびに影響を受けた組織における自己抗体および免疫複合体蓄積を減少させることであり得る。
M281産生:軽鎖および重鎖を産生する細胞培養物を遠心分離および濾過によって浄化し、その後に界面活性剤処理を用いたウイルス不活化が続いた。ウイルス不活化の後、材料をプロテインAカラムに適用して、工程に関連した不純物(例えば、宿主細胞タンパク質(HCP)、DNA、および培地添加物)を除去した。溶出液をアニオン交換カラムおよびウイルス除去フィルターに適用した。ウイルス除去の後、かつ濃縮ならびにpH6.5の25mMリン酸ナトリウムおよび25mM塩化ナトリウムのバッファーを使用した透析濾過の前に、30kDa公称分子量カットオフのポリエーテルスルホン膜を通したさらなる濾過を実施した。8.7% w/wの最終濃度までのトレハロース、および0.01%重量/体積(w/v)の最終濃度までのポリソルベート80の添加によって、材料を製剤化した。製剤バッファー(25mMリン酸ナトリウム、25mM塩化ナトリウム、8.7%トレハロース、0.01% w/vポリソルベート80、pH6.5)を用いて、M281を30mg/mL(27〜33mg/mL域)の目標まで希釈する。
本明細書において記載される方法を使用して産生され、M281抗体を含有する組成物において、SDSを用いた非還元キャピラリー電気泳動(NR CE−SDS)によってサイズバリアント種が再現性よく検出され、分析された。
M281の組成物を調製し、NR CE−SDSによって分析した。NR CE−SDSによって分析されるM281組成物の電気泳動図読み取りにより、保持時間26〜27分間を有する一方のピーク、および保持時間27.5〜29分間を有する他方のピークという2つの分離したピークが示された(図1)。後者のピークは、完全に組み立てられた軽鎖−重鎖−重鎖−軽鎖(LC−HC−HC−LC)に相当し、一方で前者のピークは、重鎖−重鎖−軽鎖(HC−HC−LCまたはHHLと称される)と比較して低い重量を有するサイズバリアント分子に相当した。NR CE−SDSによって検出されるサイズバリアント分子のレベルは、すべての下流のプロセシングステップ、GMP DSおよびDPロットの間、ならびに安定性調査の間、総タンパク質含有量の約4.0〜4.5パーセントにとどまった(データ示さず)。加えて、250Lの試験的レベルからGMP 2000L規模への規模拡大の間、NR CE−SDSによって検出されるこのサイズバリアントのレベルの有意な変化はなかった。このサイズバリアントのレベル。組成物が、サンプル調製の間にまたはCE−SDS分析の前にインキュベーション温度の増加(例えば、37℃から70℃へ)等の変性条件に曝露された場合、M281組成物におけるサイズバリアントの形成は増加した。
M281組成物におけるサイズバリアント種の分子質量を判定するために、M281組成物を、質量分析と連動した疎水性相互作用液体クロマトグラフィー(HILIC LC−MS)、直接エレクトロスプレーイオン化質量分析を有するマイクロチップゾーン電気泳動分離、およびゲル電気泳動によって分離されたタンパク質の非還元トリプシン消化、その後に続く質量分析と連動したナノ液体クロマトグラフィーを含めた3つの方法によって分析した。
HILIC LC−MSによるM281組成物の分析により、HILIC分離のUVクロマトグラムで12.5分間の保持時間を中心とするピークが明らかとなり(図2A)、それは、質量分析によって、12.42分間の保持時間を中心とする一方のピークおよび12.68分間の保持時間を中心とする他方という2つの種に分けられた(図2B)。12.42分間および12.68分間の保持時間のピークにおける分子質量の分布を、両ピークに関するマススペクトルのデコンボリューションによって判定した。保持時間12.42分間でのピークにおける種のマススペクトルのデコンボリューションにより、119,277Daの支配的な種を含む複数のサイズバリアントが明らかとなった(図3A)。119,277Daの前述の支配的な種は、ジスルフィド結合のβ脱離による予想産物である、不対重鎖における位置219でシステインを置き換えたデヒドロアラニンを有する重鎖−重鎖−軽鎖(HC−HC−LCまたはHHLと称される)に対する119,177Daという理論的質量に近かった(図4)。保持時間12.68分間でのピークにおける種のマススペクトルのデコンボリューションにより、119,329Daの支配的な種を含む複数のサイズバリアントが明らかとなった(図3B)。119,329Daの前述の支配的な種は、システイン化された(cysteinylated)不対重鎖を有する重鎖−重鎖−軽鎖(HC−HC−LCまたはHHLと称される)に対する119,329Daという理論的質量に近かった。
Claims (12)
- 配列番号2のアミノ酸配列を含む重鎖および配列番号1のアミノ酸配列を含む軽鎖を含む抗体(LHHL)を含む薬学的組成物であって、前記組成物は、140,500〜143,000Daの分子量を有する主要タンパク質構成要素、および分子量119,150〜119,350Daの副次的タンパク質構成要素を含み、前記主要構成要素は、前記組成物におけるタンパク質の少なくとも80重量%であり、前記副次的構成要素は、前記組成物におけるタンパク質の少なくとも1重量%である、薬学的組成物。
- 前記主要タンパク質構成要素は、前記組成物におけるタンパク質の少なくとも93重量%である、請求項1に記載の薬学的組成物。
- 前記副次的タンパク質構成要素は、2本の重鎖および1本の軽鎖を含む抗体バリアントを含む、請求項1に記載の薬学的組成物。
- 前記抗体バリアントは、不対重鎖および対合重鎖および軽鎖を含む、請求項3に記載の薬学的組成物。
- 前記抗体バリアントは、位置219におけるCがデヒドロアラニンによって置き換えられている、配列番号2のアミノ酸配列を含むポリペプチドを含む不対重鎖を含む、請求項3に記載の薬学的組成物。
- 前記副次的タンパク質構成要素は、a)不対重鎖および対合重鎖および軽鎖を含む第1の抗体バリアント;ならびにb)位置219におけるCがデヒドロアラニンによって置き換えられている、配列番号2のアミノ酸配列を含むポリペプチドを含む不対重鎖を含む第2の抗体バリアントを含む、請求項1に記載の薬学的組成物。
- 配列番号2のアミノ酸配列を含む重鎖および配列番号1のアミノ酸配列を含む軽鎖を含む抗体(LHHL)の組成物を提供するステップ;
前記組成物が、145,000〜160,000Daの分子量を有する主要タンパク質構成要素、および119,150〜119,350Daの分子量を有する副次的タンパク質構成要素を含むかどうかを判定するステップ;
前記組成物が、145,000〜160,000Daの分子量を有する主要タンパク質構成要素、および119,150〜119,350Daの分子量を有する副次的タンパク質構成要素を含む場合にのみ、前記組成物と1つまたは複数の薬学的に許容される賦形剤とを組み合わせて薬学的組成物を調製するステップ
を含む、請求項1から6のいずれか一項に記載の薬学的組成物を調製するための方法。 - 前記調製された薬学的組成物は、28〜32mg/mlの、配列番号2のアミノ酸配列を含む重鎖および配列番号9のアミノ酸配列を含む軽鎖を含む抗体(LHHL)を含む、請求項7に記載の方法。
- 前記調製された薬学的組成物は、9〜11mg/mlの、配列番号24のアミノ酸配列を含む重鎖および配列番号19のアミノ酸配列を含む軽鎖を含む抗体を含む、請求項7に記載の方法。
- 前記主要構成要素が前記組成物におけるタンパク質の少なくとも90重量%であり、前記副次的構成要素が前記組成物におけるタンパク質の少なくとも3重量%である場合にのみ、前記組成物と1つまたは複数の薬学的に許容される賦形剤とを組み合わせて薬学的組成物を調製するステップをさらに含む、請求項7に記載の方法。
- 前記判定するステップは、電気泳動またはクロマトグラフィーを含む、請求項7に記載の方法。
- 前記提供するステップは、前記重鎖および前記軽鎖を発現する細胞を培養するステップを含む、請求項7に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862701367P | 2018-07-20 | 2018-07-20 | |
US62/701,367 | 2018-07-20 | ||
PCT/US2019/042615 WO2020018910A1 (en) | 2018-07-20 | 2019-07-19 | Fcrn antibody compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021531347A true JP2021531347A (ja) | 2021-11-18 |
Family
ID=69165189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021526405A Pending JP2021531347A (ja) | 2018-07-20 | 2019-07-19 | Fcrn抗体組成物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210340251A1 (ja) |
EP (1) | EP3823978A4 (ja) |
JP (1) | JP2021531347A (ja) |
KR (1) | KR20210105873A (ja) |
CN (1) | CN113518783A (ja) |
AU (1) | AU2019307959A1 (ja) |
BR (1) | BR112021000755A2 (ja) |
CA (1) | CA3106670A1 (ja) |
CR (1) | CR20210076A (ja) |
EA (1) | EA202190264A1 (ja) |
IL (1) | IL280278A (ja) |
JO (1) | JOP20210013A1 (ja) |
MX (1) | MX2021000788A (ja) |
PH (1) | PH12021550082A1 (ja) |
SG (1) | SG11202100419UA (ja) |
WO (1) | WO2020018910A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3250610T3 (da) | 2015-01-30 | 2023-10-30 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf |
EP3723802A1 (en) | 2017-12-13 | 2020-10-21 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
US20220259308A1 (en) * | 2019-08-01 | 2022-08-18 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
TW202328184A (zh) * | 2021-08-13 | 2023-07-16 | 大陸商舒泰神(北京)生物製藥股份有限公司 | 特異性識別fcrn的抗體及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018023136A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
JP2018504907A (ja) * | 2015-01-30 | 2018-02-22 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI547287B (zh) * | 2008-04-25 | 2016-09-01 | 戴埃克斯有限公司 | Fc受體結合蛋白 |
BR112013030352B1 (pt) * | 2011-06-02 | 2020-05-19 | Dyax Corp | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
CN112142843A (zh) * | 2013-12-24 | 2020-12-29 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
-
2019
- 2019-07-19 AU AU2019307959A patent/AU2019307959A1/en active Pending
- 2019-07-19 EA EA202190264A patent/EA202190264A1/ru unknown
- 2019-07-19 CA CA3106670A patent/CA3106670A1/en active Pending
- 2019-07-19 EP EP19838652.6A patent/EP3823978A4/en active Pending
- 2019-07-19 US US17/260,334 patent/US20210340251A1/en active Pending
- 2019-07-19 JP JP2021526405A patent/JP2021531347A/ja active Pending
- 2019-07-19 SG SG11202100419UA patent/SG11202100419UA/en unknown
- 2019-07-19 JO JOP/2021/0013A patent/JOP20210013A1/ar unknown
- 2019-07-19 WO PCT/US2019/042615 patent/WO2020018910A1/en unknown
- 2019-07-19 CR CR20210076A patent/CR20210076A/es unknown
- 2019-07-19 MX MX2021000788A patent/MX2021000788A/es unknown
- 2019-07-19 BR BR112021000755-5A patent/BR112021000755A2/pt unknown
- 2019-07-19 CN CN201980061787.3A patent/CN113518783A/zh active Pending
- 2019-07-19 KR KR1020217003739A patent/KR20210105873A/ko unknown
-
2021
- 2021-01-13 PH PH12021550082A patent/PH12021550082A1/en unknown
- 2021-01-19 IL IL280278A patent/IL280278A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018504907A (ja) * | 2015-01-30 | 2018-02-22 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
WO2018023136A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3823978A1 (en) | 2021-05-26 |
WO2020018910A1 (en) | 2020-01-23 |
MX2021000788A (es) | 2021-07-21 |
BR112021000755A2 (pt) | 2021-04-13 |
IL280278A (en) | 2021-03-25 |
CN113518783A (zh) | 2021-10-19 |
KR20210105873A (ko) | 2021-08-27 |
AU2019307959A1 (en) | 2021-02-04 |
SG11202100419UA (en) | 2021-02-25 |
CA3106670A1 (en) | 2020-01-23 |
CR20210076A (es) | 2021-09-02 |
US20210340251A1 (en) | 2021-11-04 |
EP3823978A4 (en) | 2022-12-14 |
JOP20210013A1 (ar) | 2021-01-19 |
EA202190264A1 (ru) | 2021-05-20 |
PH12021550082A1 (en) | 2021-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230064544A1 (en) | Anti-ctla4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
JP2021531347A (ja) | Fcrn抗体組成物 | |
KR102483016B1 (ko) | FcRn 항체 및 이의 사용 방법 | |
JP5553963B2 (ja) | 組換え抗体をリフォールディングする方法 | |
JP7442575B2 (ja) | Fcrn抗体及びその使用方法 | |
EP3581245A1 (en) | Antibodies to tau and uses thereof | |
JP7449351B2 (ja) | タンパク質二量体化を特徴解析するためのシステムおよび方法 | |
JP2021531346A (ja) | Fcrn抗体の組成物およびその使用の方法 | |
WO2016031932A1 (ja) | アルカリ洗浄によるFc領域を有するタンパク質の製造方法 | |
WO2022173036A1 (ja) | ヒト変性crp特異的な中和抗体、並びにそれを含む医薬及び抗炎症剤 | |
BR122022014045B1 (pt) | Método para identificar sítios de interação não covalente ou interfaces de dimerização em um medicamento proteico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240423 |